Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
Home > News > Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
Oligomerix > News > Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
By accessing our website or software provided by our third-party vendors, you consent to accept cookies, (including other identifiers). These include pieces of text that are stored on your computer or device. This site uses cookies and Google Analytics to improve navigation, minimize the need to reenter information previously entered on forms, personalize messages, and collect statistical information to improve site navigation and provide content of greatest interest to users.Ok